Bayesian Design in Clinical Trials

In the last decade, the number of clinical trials using Bayesian methods has grown dramatically. Nowadays, regulatory authorities appear to be more receptive to Bayesian methods than ever. The Bayesian methodology is well suited to address the issues arising in the planning, analysis, and conduct of...

Full description

Saved in:
Bibliographic Details
HerausgeberIn:
Sonstige:
Year of Publication:2022
Language:English
Physical Description:1 electronic resource (190 p.)
Tags: Add Tag
No Tags, Be the first to tag this record!
LEADER 04586nam-a2201009z--4500
001 993545956604498
005 20240430192558.0
006 m o d
007 cr|mn|---annan
008 202203s2022 xx |||||o ||| 0|eng d
035 |a (CKB)5400000000045321 
035 |a (oapen)https://directory.doabooks.org/handle/20.500.12854/79674 
035 |a (EXLCZ)995400000000045321 
041 0 |a eng 
100 1 |a Berchialla, Paola  |4 edt 
245 1 0 |a Bayesian Design in Clinical Trials 
260 |a Basel  |b MDPI - Multidisciplinary Digital Publishing Institute  |c 2022 
300 |a 1 electronic resource (190 p.) 
336 |a text  |b txt  |2 rdacontent 
337 |a computer  |b c  |2 rdamedia 
338 |a online resource  |b cr  |2 rdacarrier 
506 |a Open access  |f Unrestricted online access  |2 star 
520 |a In the last decade, the number of clinical trials using Bayesian methods has grown dramatically. Nowadays, regulatory authorities appear to be more receptive to Bayesian methods than ever. The Bayesian methodology is well suited to address the issues arising in the planning, analysis, and conduct of clinical trials. Due to their flexibility, Bayesian design methods based on the accrued data of ongoing trials have been recommended by both the US Food and Drug Administration and the European Medicines Agency for dose-response trials in early clinical development. A distinctive feature of the Bayesian approach is its ability to deal with external information, such as historical data, findings from previous studies and expert opinions, through prior elicitation. In fact, it provides a framework for embedding and handling the variability of auxiliary information within the planning and analysis of the study. A growing body of literature examines the use of historical data to augment newly collected data, especially in clinical trials where patients are difficult to recruit, which is the case for rare diseases, for example. Many works explore how this can be done properly, since using historical data has been recognized as less controversial than eliciting prior information from experts’ opinions. In this book, applications of Bayesian design in the planning and analysis of clinical trials are introduced, along with methodological contributions to specific topics of Bayesian statistics. Finally, two reviews regarding the state-of-the-art of the Bayesian approach in clinical field trials are presented. 
546 |a English 
650 7 |a Humanities  |2 bicssc 
650 7 |a Social interaction  |2 bicssc 
653 |a dose-escalation 
653 |a combination study 
653 |a modelling assumption 
653 |a interaction 
653 |a adaptive designs 
653 |a adaptive randomization 
653 |a Bayesian designs 
653 |a clinical trials 
653 |a predictive power 
653 |a target allocation 
653 |a Bayesian inference 
653 |a highest posterior density intervals 
653 |a normal approximation 
653 |a predictive analysis 
653 |a sample size determination 
653 |a bayesian meta-analysis 
653 |a clustering 
653 |a binary data 
653 |a priors 
653 |a frequentist validation 
653 |a Bayesian 
653 |a rare disease 
653 |a prior distribution 
653 |a meta-analysis 
653 |a sample size 
653 |a bridging studies 
653 |a distribution distance 
653 |a oncology 
653 |a phase I 
653 |a dose-finding 
653 |a dose–response 
653 |a bayesian inference 
653 |a prior elicitation 
653 |a latent dirichlet allocation 
653 |a clinical trial 
653 |a power-prior 
653 |a poor accrual 
653 |a Bayesian trial 
653 |a cisplatin 
653 |a doxorubicin 
653 |a oxaliplatin 
653 |a dose escalation 
653 |a PIPAC 
653 |a peritoneal carcinomatosis 
653 |a randomized controlled trial 
653 |a causal inference 
653 |a doubly robust estimation 
653 |a propensity score 
653 |a Bayesian monitoring 
653 |a futility rules 
653 |a interim analysis 
653 |a posterior and predictive probabilities 
653 |a stopping boundaries 
653 |a Bayesian trial design 
653 |a early phase dose finding 
653 |a treatment combinations 
653 |a optimal dose combination 
776 |z 3-0365-3333-8 
700 1 |a Baldi, Ileana  |4 edt 
700 1 |a Berchialla, Paola  |4 oth 
700 1 |a Baldi, Ileana  |4 oth 
906 |a BOOK 
ADM |b 2024-05-01 16:10:54 Europe/Vienna  |f system  |c marc21  |a 2022-04-04 09:22:53 Europe/Vienna  |g false 
AVE |i DOAB Directory of Open Access Books  |P DOAB Directory of Open Access Books  |x https://eu02.alma.exlibrisgroup.com/view/uresolver/43ACC_OEAW/openurl?u.ignore_date_coverage=true&portfolio_pid=5338079540004498&Force_direct=true  |Z 5338079540004498  |b Available  |8 5338079540004498